Rumex crispus root extract and emodin show antiviral activity against HCoV-OC43
Health News

Rumex crispus root extract and emodin show antiviral activity against HCoV-OC43

By Dr. Nathan Cole · · 3 min read

Why OC43 matters for antiviral screening

Coronaviruses are a diverse family of pathogens affecting humans and animals. They cause conditions ranging from common colds to severe respiratory illnesses like COVID-19. Other human coronaviruses, including HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, account for a significant share of common cold cases. HCoV-OC43 belongs to the Betacoronavirus genus, which also includes SARS-CoV-2 and MERS-CoV. Because of its phylogenetic link to these highly pathogenic agents and its relatively low pathogenicity, HCoV-OC43 serves as a surrogate model for initial screening and evaluation of potential antiviral agents. Studying antiviral compounds against HCoV-OC43 can provide valuable insights for developing therapeutic candidates targeting human coronaviruses, including SARS-CoV-2.

Need for diverse antiviral mechanisms

The positive-sense RNA genome of coronaviruses can undergo genetic changes that lead to new variants. These variants may affect transmissibility, pathogenicity, and sensitivity to antiviral treatments. Therefore, ongoing efforts to identify antiviral agents with diverse mechanisms of action are necessary to combat existing and emerging coronavirus infections. Plant phytochemicals have offered various approaches to inhibit coronavirus infection. These antiviral compounds can serve as alternative strategies for treating coronavirus-related diseases.

Study design and key findings

In this study, we evaluated the antiviral activity of Rumex crispus root extracts and their solvent fractions against HCoV-OC43. We also performed phytochemical analysis to identify bioactive constituents associated with the observed antiviral activity. Our results demonstrate the anticoronavirus activity of R. crispus root fractions and identify emodin as one of the compounds that potentially contributes to this effect.

General experimental procedures are described in the materials and methods section. Nuclear magnetic resonance (NMR) spectra were recorded at 300 MHz for protons and, where measured, at 75 MHz for carbon-13, using methanol-d4 or DMSO-d6 as solvent, as indicated in the supplementary information legends. Supplementary NMR spectra for emodin (compound 12) and citreorosein (compound 9) were recorded on an AVANCE III-400 spectrometer (Bruker, Billerica, MA, USA) at 400 MHz, with DMSO-d6 as solvent. Thin-layer chromatography (TLC) was performed on silica gel and C-18 phase plates (Merck, Rahway, NJ, USA), respectively. Column chromatography was carried out using silica gel (60 Å, 230–400 mesh ASTM; Merck, Germany) and C-18 silica gel (ODS-A, S-75 µm; YMC, Kyoto, Japan).

Materials and methods

The plant material was purchased from a traditional herbal medicine shop in the Republic of Korea in August 2023 and was authenticated by Dr. J. H. Kim. A reference specimen (RC 23) was deposited at the Herbarium of the Department of Herbal Culture Research, National Institute of Horticultural and Herbal Sciences, Republic of Korea.

Plant material and extraction

R. crispus roots (4 kg) were extracted three times with 99% ethanol (30 L) in a double boiler at 60 °C. The filtered solvent was evaporated under reduced pressure to obtain an ethanol extract (350 g). The condensed extract was suspended in 8 L of water and then fractionated sequentially into n-hexane (30 g), ethyl acetate (EA, 38 g), and aqueous layer (262 g) fractions. The n-hexane fraction was subjected to column chromatography on silica gel, using a solvent gradient of n-hexane and EA (10:0–1:4), yielding 15 fractions (RCh1–RCh15). Fraction RCh7 was chromatographed with distilled water and methanol (1:0–1:5) on C-18, yielding two compounds, 12 (450 mg) and 13 (320 mg), and three fractions (RCh71–RCh74). Compound 11 (37 mg) was purified from RCh43 using C-18 column chromatography with an isocratic solvent system of methanol and distilled water (3:1).

Extraction and isolation procedure

Fraction RCh12 was separated (1:0–1:2), yielding two compounds, 9 (25 mg) and 10 (14 mg). The EA fraction was subjected to column chromatography with chloroform and methanol (20:1–1:3), yielding twenty-two fractions (ECe1–ECe12). Fraction ECe4 was subjected to a gradient (1:0–1:3), yielding two compounds, 8 (54 mg) and 7 (47 mg), and five fractions (ECe41–ECe45). Fraction ECe43 was further purified to obtain compound 6 (39 mg). Fraction ECe7 was subjected to a gradient (15:0–1:1), yielding seven fractions (ECe71–ECe77). Fraction ECe74 was purified by C-18 column chromatography using a solvent ratio (1.5:1), yielding three compounds, 5 (25 mg), 4 (21 mg), and 3 (16 mg). Fraction ECe10 was subjected to a gradient (10:1–1:3), yielding five fractions (ECe101–ECe105).

Leave a comment

Every comment is read before it goes live. You will see it published once approved. You can send at most 2 comments per hour.